Company

Location

Date

Amt. (M)

Details

23andMe Inc.

Mountain View, Calif.

5/23

ND

Company closed a Series A round with investments from Genentech Inc., Google Inc., MDV- Mohr Davidow Ventures and New Enterprise Associates

Advanced BioHealing Inc.

La Jolla, Calif.

5/31

$4.5

Advanced BioHealing raised $4.5M in a second tranche of its Series C round, bringing the total to $30M; the first part was done in February; new investors were Safeguard Scientifics Inc. and CDIB BioScience Ventures

Arete Therapeutics Inc.

Hayward, Calif.

5/23

$35

Arete added $35M to a Series A round, bringing the total raised to $51M; the company raised $16M in the first tranche in February 2005; investors included Frazier Healthcare, Alta Partners, Three Arch Partners and Burrill & Co., as well as Altitude Life Science Ventures

Aveo Pharmaceuticals Inc.

Cambridge, Mass.

5/3

$53

Aveo raised $53M in a Series D round with new investors Biogen Idec Inc., Bessemer Venture Partners, Merlin BioMed Group, Mitsubishi UFJ Financial Group and Vatera Holdings, as well as Schering-Plough Corp.; existing investors also participated, including Highland Capital Partners, Venrock Associates, MPM Capital, Prospect Ventures, Flagship Ventures, Oxford Bioscience Partners, Greylock Partners, Lotus Biosciences and GE Capital

Avid Radio- pharmaceuticals Inc.

Philadelphia

5/9

$26

Avid raised $26M in the Series C round co-led by AllianceBernstein LP and Safeguard Scientifics Inc.; other investors were Pfizer Strategic Investments Group, Lilly Ventures, RK Venture Group and BioAdvance

BaroFold Inc.

Boulder, Colo.

5/24

$12

BaroFold raised $12M in a Series A financing co-led by HBM BioVentures Ltd. and Boulder Ventures Ltd. with participation by the Pierls Foundation and other seed round investors

Biolex Therapeutics Inc.

Pittsboro, N.C.

5/24

$30

Biolex raised $30M in the Series C round led by Investor Growth Capital; other investors were JP Morgan Securities Inc. and Easton Capital, as well as Quaker BioVentures, Polaris Venture Partners, Intersouth Partners, Mitsui & Co. Venture Partners, Johnson & Johnson Development Corp. and Dow Venture Capital

BT Pharma

Toulouse, France

5/29

€1.3 ($1.75)

BT Pharma closed a $1.75M bridge financing investment from current shareholders and a new private investor

CardioMetabolics Inc.

Edmonton, Alberta

5/31

C$4.1 ($3.8)

CardioMetabolics raised $3.8M in a financing led by Canaccord Capital Corp.

Ception Therapeutics Inc.

Malvern, Pa.

5/31

$14.7

Ception raised $14.7M in a Series C financing round, bringing the round's total to $77M; the initial $63M investment was done in January; investors were Third Point LLC and Greenlight Capital

Combinent BioMedical Systems Inc.

Cambridge, Mass.

5/7

ND

Cytyc Corp. made a venture investment of an undisclosed amount in Combinent BioMedical

Conatus Pharmaceuticals Inc.

San Diego

5/9

$22

Conatus completed the $22M second closing of its $27.5M Series A financing begun in January; investors were Aberdare Ventures, Advent Venture Partners, Bay City Capital and Gilde Healthcare Partners

DermTech International Inc.*

La Jolla, Calif.

5/30

$10

DermTech raised part of a $10M round

Intrexon Corp.

Blacksburg, Va.

5/15

$25

Intrexon raised $25M in a Series C1 round backed entirely by Third Security LLC

IRX Therapeutics

New York

5/24

$12.5

IRX raised $12.5M through a convertible note offering

Marcadia Biotech

Carmel, Ind.

5/15

$15

Marcadia completed a $15M Series A round co- led by Frazier Healthcare Ventures and 5AM Ventures; it also included Twilight Venture Partners

Morria Bio- pharmaceuticals plc

London

5/10

£1.6 ($3.8)

Morris raised $3.8M in a round led by Charles Street Securities Inc.

Neosil Inc.

Emeryville, Calif.

5/15

$10

Neosil received $10M of venture debt financing from Hercules Technology Growth Capital Inc.

Noxxon Pharma AG

Berlin

5/3

€37 ($50)

Noxxon raised $50M in a Series C round with investors TVM Capital, Sofinnova Partners and Edmond de Rothschild Investment Partners, as well as DEWB AG, FCP OP Medical BioHealthTrends, the Dieckell Group, Seventure Dow Venture Capital, IBG Beteiligungsgesellschaft SachsenAnhalt mbH, VC Fonds Berlin GmbH and others

Pasteuria Bioscience

Alachua, Fla.

5/4

$5.3

Pasteuria completed a $5.3M Series B round led by LSP BioVentures, which joined Advantage Capital and Gordon River Capital

Portola Pharmaceuticals Inc.

South San Francisco

5/7

$70

Portola raised $70M in the Series C financing; investors were Brookside Capital, AllianceBernstein LP, Teachers' Private Capital, Goldman Sachs, T. Rowe Price, IBT Management Corp., China Investment & Development Co., Abing- worth, Alta Partners, Advanced Technology Ventures, Frazier Healthcare, MPM Capital, Prospect Ventures and Sutter Hill Ventures

ProCertus BioPharm Inc.

Madison, Wis.

5/10

$2.23

ProCertus closed $2.23M in a Series A round led by Venture Investors LLC, which was joined by existing investors, including Novartis Venture Fund

ProtAffin Biotechnologie

Graz, Austria

5/9**

€2.65 ($3.6)

ProtAffin raised $3.6M in a Series A round led by Aescap Venture Management BV

Ann Arbor, Mich.

5/22

$44

QuatRx brought in $44M in a Series E round led by Venrock; other investors were T. Rowe Price, Catella Healthcare, Hercules Technology Growth Capital and a number of existing investors; Aquilo Partners Inc. was the placement agent

Sidec Technologies AB

Stockholm, Sweden

5/7

SEK68.5 ($10.2)

Sidec raised $10.2M in private funding led by Earlybird Venture Capital; Swedish Investor Growth Capital and Industrifonden also participated

Solace Pharmaceuticals Inc.

Boston

5/1

$15

Solace raised $15M in a Series A financing co-led by Polaris Venture Partners and InterWest Partners, with participation from PureTech Ventures

StrataGent Life Sciences Inc.

San Jose, Calif.

5/10

$6.65

StrataGent raised $6.65 in a tranche of a planned $16M Series B financing round; it was led by Essex Woodlands Health Ventures, and included Quantum Technology Partners and Aphelion Capital

Talima Therapeutics Inc.

Santa Clara, Calif.

5/29

$19

Talima raised $19M in a second financing round; U.S. Venture Partners and Latterell Venture Partners led the round, joining existing investors De Novo Ventures and Palo Alto Healthcare

Tempo Pharmaceuticals Inc.

Cambridge, Mass.

5/23

$12.1

Tempo closed a $12.1M Series A financing; Venrock and Polaris Venture Partners co-led the round, with participation from Lux Capital and William Rastetter